TP53 and cancer: Of particular note, flexicates ΛFe-[Fe2L2c3]Cl4 and ΔFe-[Fe2L2c3]Cl4 were both ∼9-fold more active against HCT116 p53–/– cancer cells than their genetically identical p53+/+ counterparts [Fig. 5(b) and(c); see SEI].